Vaccines and Infectious Diseases · global
Tetravalent Shigella Vaccine Phase 2 Results Reported: Infants Produce Antibodies, Adult Challenge Trial Shows Signal of Protection
S4V2 has made progress on different fronts in infant and adult studies, but whether the protection seen in adults extends to young children and covers all four serotypes remains for subsequent trials to determine.
A vaccine to prevent Shigella infection must both elicit immune responses in young children and demonstrate that those responses can reduce the risk of illness. On November 9, Valneva announced results from two Phase 2 trials of its tetravalent vaccine candidate Shigella4V2 (S4V2), providing preliminary evidence of antibody responses in infants and protection in adults, respectively. Clinical research still needs to establish the crucial link between the two.
The infant trial S4V02, conducted in Kenya, enrolled 110 infants approximately nine months old and compared two S4V2 dose levels with a meningococcal control vaccine, all administered in two doses. The study primarily assessed safety and immune responses; it did not directly test whether the vaccine could reduce illness in infants.
According to the company's announcement, after two doses, infants had significantly higher levels of anti-lipopolysaccharide IgG antibodies against all four targeted Shigella serotypes than those in the control group. Antibody concentrations peaked after the second dose and remained above pre-vaccination levels six months later. Most adverse events were mild to moderate, with no statistically significant difference from the control group. All adverse events considered related to vaccination resolved without complications.
The other study, S4V03, used a controlled human infection model in adults. Under the study design, healthy adults received two doses of vaccine or placebo and were then exposed to the Shigella sonnei 53G strain under controlled conditions to compare illness between the two groups. This allowed researchers to directly observe protection against a specific strain.
Valneva said the adult trial met its primary endpoint, with a significantly lower incidence of Shigella sonnei disease in the vaccine group than in the placebo group. However, the announcement did not provide a vaccine efficacy percentage, case counts for each group, or confidence intervals, so the magnitude of the effect and the precision of the estimate cannot yet be assessed.
The two sets of results also have different limits to their applicability: antibody production in infants does not establish that the vaccine prevents disease. Similarly, a signal of protection in adults challenged with a single strain does not directly establish that the vaccine can protect young children under everyday exposure conditions or provide equal efficacy against all four targeted serotypes.
The company is reviewing the full data to determine the next steps in development and said that dose levels and vaccination schedules still require further evaluation. These results provide a basis for continued research on S4V2. The central question for the next stage is how to translate the preliminary immune responses and signals of protection into measurable disease prevention in the target pediatric population.